Quadrivalent FluMist vaccine available in Autumn 2013...

[Guest guest]

you my have to sign up to log on but it is free

In the US - currently we have a trivalent one (3 strains) - Autumn 2013,

4 strains

www.medscape.com/viewarticle/759517

March 1, 2012 ­ Designed to cover more viral bets, the first quadrivalent

vaccine to prevent seasonal influenza received approval yesterday from

the US Food and Drug Administration (FDA).

The vaccine, FluMist Quadrivalent (MedImmune), will be available

for the 2013-2014 flu season. Administered as a nasal spray like the

already-approved trivalent FluMist seasonal vaccine, it contains

live but weakened forms of viral strains as opposed to inactive ones. The

vaccine is indicated for individuals ages 2 years through 49

years.

All FDA-approved seasonal flu vaccines now on the market consist of 3

strains of influenza virus: 2 of influenza A and 1 of influenza B.

FluMist Quadrivalent will contain 2 strains of influenza A and 2 strains

of influenza B from the B/Yamagata and B/ lineages. A strain from

the B/Yamagata lineage is in the current trivalent seasonal

vaccine.

The FDA stated that during a typical flu season, 2 different strains of

influenza B may be circulating, or else the strain in circulation may not

match the B strain selected for the vaccine. Including a second influenza

B strain improves the odds of protecting Americans against whatever is

circulating.

The demographic profile of the influenza B virus figured into the FDA's

decision.

" Illness caused by influenza B virus affects children, particularly

young and school-aged, more than any other population, " said

Midthun, MD, director of the FDA's Center for Biologics Evaluation and

Research, in an agency news release. " A vaccine containing the four

virus strains most likely to spread and cause illness during the

influenza season offers an additional option to aid in influenza

prevention efforts. "

The agency said that studies conducted previously for the trivalent

FluMist vaccine as well as 3 new clinical studies involving some 4000

children and adults established that FluMist Quadrivalent is safe and

effective, with an immune response similar to that of the trivalent

version.

Adverse reactions to FluMist Quadrivalent resemble those for FluMist ­

runny or stuffy nose in both children and adults, and headaches and sore

throat in adults.

More information about the FDA's approval of FluMist Quadrivalent is

available on the agency's

Web site.

Sheri Nakken, former R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/ Homeopathy

http://homeopathycures.wordpress.com

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start March 1 & 8